Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Forecast Price Target with 40.45% Profit: QuantWave Analysis

August 08, 2023
ELI LILLY AND COMPANY stock (ticker: LLY) recently achieved the price target forecast set by QuantWave, resulting in a profit of 40.45%. The forecast signal was generated on April 17, 2023, when the stock was trading at 365.32 $. The predicted direction was long, and on August 8, 2023, the stock reached the target price of 513.09 $.

This success is a testament to the accuracy and efficiency of QuantWave's analytical capabilities. The achievement of the forecast price target highlights the platform's ability to provide valuable insights for investors seeking profitable opportunities in the stock market.

Market analysis indicates that ELI LILLY AND COMPANY's stock movement was influenced by several factors, including positive developments in the company's pipeline of pharmaceutical products, strong financial performance, and overall market trends favoring the healthcare sector.

QuantWave, as an automated forecasting platform, offers users access to predictions for a wide range of stocks, presenting opportunities for potential profits. For investors looking to enhance their understanding of QuantWave's investment strategy, QuantSchool provides comprehensive educational resources to learn the key principles of generating consistent income using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target, Generating 18.65% Profit for QuantWave Users  ~1 min.

ELI LILLY AND COMPANY's stock recently reached the price target forecasted by QuantWave on 2024-08-06. The forecast signal indicated a short position, with the stock priced at 786.06 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Short Price Target Forecast Resulting in 19.15% Profit for QuantWave Users  ~2 min.

ELI LILLY AND COMPANY (LLY) investors recently saw the stock hitting a short price target forecast set by QuantWave, resulting in a substantial profit of 19.15%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Resulting in 19.55% Profit - QuantWave Success  ~1 min.

ELI LILLY AND COMPANY stock has successfully reached the price target as forecasted by QuantWave, resulting in a profitable 19.55% gain for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 22.51% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved its forecasted price target as predicted by QuantWave, a leading automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Price Target with 22.13% Profit on QuantWave Platform  ~2 min.

ELI LILLY AND COMPANY (LLY) recently achieved the forecast price target on the QuantWave platform, resulting in a remarkable 22.13% profit for investors who followed the short signal....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....


BMYJanuary 10, 2025Bristol Myers Squibb Company: A Leader in the Pharmaceutical Industry  ~2 min.

Bristol Myers Squibb Company (BMY) is a renowned pharmaceutical company that continues to make waves in the industry....


REGNApril 8, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target with 20% Profit: QuantWave Analysis  ~1 min.

In a recent success for QuantWave's forecasting platform, the stock of REGENERON PHARMACEUTICALS, INC. has hit its price target with a 20% profit margin....


REGNOctober 13, 2022REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 22.38% Profit: QuantWave's Success  ~2 min.

On August 4, 2022, QuantWave issued a long signal for REGENERON PHARMACEUTICALS, INC. with a price target of $749.35. The stock, which was at $612....


LLYJanuary 10, 2025Lilly to participate in J.P. Morgan Healthcare Conference  ~2 min.

Eli Lilly and Company (NYSE: LLY) has confirmed its participation in the prestigious J.P. Morgan Healthcare Conference....


GSKJanuary 11, 2025Exciting Developments for GSK plc: Breakthrough Therapy Designation Granted for ADC  ~2 min.

GSK plc, a leading pharmaceutical company, has achieved a significant milestone in its journey towards developing breakthrough treatments....